Search the Newsreel

Johnson & Johnson settling talc baby powder lawsuits for $5.5 billion

Johnson & Johnson announced an agreement Monday to pay $5.5 billion to resolve tens of thousands of lawsuits claiming its talc-based baby powder and other talc products caused ovarian cancer, a settlement the company said would bring finality to 15 years of litigation. The …

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least …

Johnson & Johnson reaches $5.5 billion baby powder settlement

View Comments

Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer Claims

Johnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Johnson & Johnson anuncia acordo de US$ 5,5 bi em ações sobre talco

Johnson & Johnson Strikes $5.5 Bln Talc Settlement Deal, Subject To 95% Claimant Approval

(RTTNews) - Johnson & Johnson (JNJ) on Monday announced that it has reached an agreement to resolve the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings. The resolution includes a $5.5 billion commitment to …

Johnson & Johnson to pay up to $5.5B to settle talc lawsuits

Wachiwit/iStock Editorial via Getty Images Johnson & Johnson (JNJ [https://seekingalpha.com/symbol/JNJ]) up 1.4% post-market Monday after saying it agreed to pay up to $5.5B to settle remaining lawsuits [https://seekingalpha.com/pr/20596634-johnson-and-johnson-announces-a-proposed-resolution-of-ovarian-talc-litigation] that alleged its talc products caused ovarian cancer. The company said it reached an agreement for …

Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues. In MedTech, J&J is a global leader in electrophysiology, circulatory restoration and heart …

Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck

Quick Read Realty Income (O) yields 5.11% with 670 consecutive monthly dividends, while Verizon (VZ) anchors the group at a 6.46% yield. All five stocks raised dividends through two recessions with cash flow covering each payout, making them viable alternatives to Social Security's 2.8% …

President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling

Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst …

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Dividend Kings are companies that have increased their dividends for 50 or more years in a row. If you're thinking of investing in one, you might be considering AbbVie (NYSE: ABBV) or Johnson & Johnson (NYSE: JNJ) stock. There are good reasons to invest …